natgillin/translations-raw huggingface dataset:
Insuman Comb 25 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insuman Comb 25 se ne sme uporabiti, če tega ni mogoče doseči, tj. suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
209 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
202 Ravnanje z injekcijskim peresnikom Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
210 Step 3.
Korak 3.
211 The injection button should be pressed all the way in.
Gumb za injiciranje je treba pritisniti povsem do konca.
213 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
214 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
207 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
215 4.5 Interaction with other medicinal products and other forms of interaction
208 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
216 Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
209 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
217 Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
210 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
218 6.
211 6.
219 Insulin pen The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca peresnika.
220 8.
213 8.
222 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
215 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
223 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
216 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
224 Handling of the pen
217 Ravnanje z injekcijskim peresnikom
225 4.8 Undesirable effects
4. 8 Neželeni učinki
226 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
General disorders and administration site conditions
219 Splošne težave in spremembe na mestu aplikacije
227 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
5.3 Preclinical safety data
220 5. 3 Predklinični podatki o varnosti
The pen in-use or carried as a spare may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct ligh.
Rok uporabnosti po prvi uporabi injekcijskega peresnika Injekcijski peresnik, ki ga uporabljate ali ga imate pri sebi za rezervo, lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
228 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 mlsuspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
Injection needles are not included in the pack.
221 Igle niso priložene.
229 Handling of the pen
222 Ravnanje z injekcijskim peresnikom
Step 2.
223 Korak 2.
230 Only needles that are compatible for use with SoloStar should be used.
Uporabljajte le igle, primerne za uporabo s SoloStarjem.
EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX
224 EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX
Insuman Comb 50 100 IU/ ml suspension for injection in a vial
Insuman Comb 50 100 i. e. / ml suspenzija za injiciranje v viali
Insuman Comb 50 is a biphasic isophane insulin suspension consisting of 50% dissolved insulin and 50% crystalline protamine insulin.
Insuman Comb 50 je dvofazna suspenzija insulina izofana, sestavljena iz 50% raztopljenega insulina in 50% kristalnega protamin- insulina.
233 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 50 contains 100 IU of insulin per ml suspension.
En mililiter suspenzije Insuman Comb 50 vsebuje 100 i. e. insulina.
Patients hypersensitive to Insuman Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Comb 50, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
234 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
227 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
235 Intercurrent illness
Sočasne bolezni
Insuman Comb 50 can be used during breastfeeding.
Zdravilo Insuman Comb 50 je med dojenjem dovoljeno uporabljati.
236 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
237 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
230 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
Insuman Comb 50 (a biphasic isophane insulin suspension with 50% dissolved insulin) is an insulin with rapid onset and moderately long duration of action.
Insuman Comb 50 (dvofazna suspenzija insulina izofana s 50% raztopljenega insulina) je insulin s hitrim začetkom in zmerno dolgim trajanjem delovanja.
238 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
239 5 ml suspension in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
5 ml suspenzija v viali (iz brezbarvnega stekla tipa 1) s prirobljeno zaporko (iz aluminija), z zamaškom (iz klorobutilne gume (tipa 1)) in s pokrovčkom, ki se odtrga (iz polipropilena).
Immediately before withdrawal from the vial into the injection syringe, the insulin must be re-suspended.
232 Tik pred izvlekom iz viale v injekcijsko brizgo je treba insulin ponovno suspendirati.
Insuman Comb 50 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulina Insuman Comb 50 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno viale.
As with all insulin preparations, Insuman Comb 50 must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insuman Comb 50 ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
Insuman Comb 50 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insuman Comb 50 se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi- Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insuman Comb 50 must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insuman Comb 50 prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
Insuman Comb 50 40 IU/ ml suspension for injection in a vial
Insuman Comb 50 40 i. e. / ml suspenzija za injiciranje v viali
Each ml contains 40 IU insulin human (equivalent to 1.4 mg).
En mililiter vsebuje 40 i. e. humanega insulina.
241 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 50 contains 40 IU of insulin per ml suspension.
En mililiter suspenzije Insuman Comb 50 vsebuje 40 i. e. insulina.
242 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
235 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
243 Intercurrent illness
Sočasne bolezni
A number of substances affect glucose metabolism and may require dose adjustment of human insulin.
236 Na presnovo glukoze vplivajo številna zdravila oz. snovi in potrebna utegne biti prilagoditev odmerka humanega insulina.
244 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter- regulation.
237 Pri mnogih bolnikih se pred znaki in simptomi nevroglikopenije pojavijo znaki adrenergične protiregulacije.
245 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
238 Večina manjših reakcij na insuline na mestu injiciranja ponavadi mine v nekaj dneh do nekaj tednih.
246 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
247 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
After resuspension, the fluid must have a uniformly milky appearance.
240 Po ponovnem suspendiranju mora biti tekočina enakomerno mlečnega videza.
Insuman Comb 50 100 IU/ ml suspension for injection in a cartridge
Insuman Comb 50 100 i. e. / ml suspenzija za injiciranje v vložku
Each ml contains 100 IU insulin human (equivalent to 3,5 mg).
En mililiter vsebuje 100 i. e. humanega insulina (kar ustreza 3, 5 mg).
250 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 50 in cartridges has been developed for use in the OptiPen series.
Insuman Comb 50 v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.
251 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
243 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
252 4.5 Interaction with other medicinal products and other forms of interaction
244 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Insuman Comb 50 can be used during breastfeeding.
Zdravilo Insuman Rapid je med dojenjem dovoljeno uporabljati.
253 Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
245 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
254 Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
246 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
255 6.
247 6.
Insulin pen
248 Insulinski injekcijski peresnik
256 The cartridges are to be used in conjunction with an insulin pen such as OptiPen and other pens suitable for Insuman cartridges and as recommended in the information provided by the device manufacturer.
Vložki se uporabljajo skupaj z insulinskim injekcijskim peresnikom kot je OptiPen in drugimi primernimi injekcijskimi peresniki za vložke Insuman in po navodilih izdelovalca injekcijskega peresnika.
Cartridges Before insertion into the pen, Insuman Comb 50 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred vstavitvijo v injekcijski peresnik mora biti Insuman Comb 50 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insuman Comb 50 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insuman Comb 50 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
Insuman Comb 50 100 IU/ ml suspension for injection in a pre-filled pen.
Insuman Comb 50 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Insuman Comb 50 is a biphasic isophane insulin suspension consisting of 50% dissolved insulin and 50% crystalline protamine insulin.
Insuman Comb 50 je dvofazna suspenzija insulina isofana, sestavljena iz 50% raztopljenega insulina in 50% kristalnega protamin- insulina.
259 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
251 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
260 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
252 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
261 Handling of the pen
Ravnanje z injekcijskim peresnikom
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
253 Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
262 Hypoglycaemia, in general the most frequent undesirable effect of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
V kliničnih preskušanjih in med marketinško
In clinical trials and during marketed use, the frequency varies with patient population and dose regimens.
254 uporabo se je pogostnost razlikovala glede na populacijo bolnikov in sheme odmerjanja.
263 General disorders and administration site conditions
255 Splošne težave in spremembe na mestu aplikacije
Common: injection site reactions Uncommon: injection site urticaria, Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
Pogosti: reakcije na mestu injiciranja Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
264 The acute toxicity was studied following subcutaneous administration in rats.
256 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
Each cartridge contains 3 balls (stainless steel).
3- ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
265 Packs of 3, 4, 5, 6, 9 or 10 pens are available.
257 Na voljo so pakiranja s 3, 4, 5, 6, 9 ali 10 injekcijskimi peresniki.
Insuman Comb 50 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insuman Comb 50 se ne sme uporabiti, če tega ni mogoče doseči, tj. suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
266 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
258 Ravnanje z injekcijskim peresnikom Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
267 Step 3.
Korak 3.
268 The injection button should be pressed all the way in.
Gumb za injiciranje je treba pritisniti povsem do konca.
Each ml contains 100 IU insulin human (equivalent to 3,5 mg).
En mililiter vsebuje 100 i. e. humanega insulina.
Each cartridge contains 3 ml suspension for injection, equivalent to 300 IU insulin.
Vsak vložek vsebuje 3 ml suspenzija za injiciranje, kar ustreza 300 i. e. insulina.
270 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
271 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
263 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
272 4.5 Interaction with other medicinal products and other forms of interaction
264 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
273 Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
265 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
274 Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
266 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
275 6.
267 6.
Not all pack sizes may be marketed.
268 Na trgu ni vseh navedenih pakiranj.
276 Insulin pen The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca injekcijskega peresnika.
Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany
269 Sanofi- Aventis Deutschland GmbH, D- 65926 Frankfurt am Main, Nemčija
279 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
271 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
280 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
272 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
281 Handling of the pen
273 Ravnanje z injekcijskim peresnikom
282 4.8 Undesirable effects
4. 8 Neželeni učinki
283 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
General disorders and administration site conditions
275 Splošne težave in spremembe na mestu aplikacije